Editorial Policy
Effective date: June 1, 2026
Our mission
NovaPharmaNews publishes pharmaceutical news and regulatory intelligence for healthcare professionals. Our editorial team monitors FDA, EMA, and APAC agency announcements, clinical trial readouts, and industry developments — and reports them with accuracy, context, and primary-source attribution.
Independence
- News coverage is independent of advertising, supplier listings, and sponsored content.
- Supplier profiles in our directory do not influence editorial rankings, headlines, or coverage decisions.
- We do not accept payment for favorable coverage of drugs, companies, or clinical programs.
Sources and fact-checking
We prioritize primary sources, including:
- Official regulatory databases and agency press releases (FDA, EMA, PMDA, NMPA, TGA, and others)
- ClinicalTrials.gov and CTIS public records
- Peer-reviewed journals and company SEC filings where relevant
Articles undergo editorial review before publication. Drug names use international nonproprietary (INN) names where applicable. We do not provide medical advice, off-label promotion, or investment recommendations.
Authors and expertise
Articles are attributed to named authors with displayed credentials (PharmD, MD, regulatory affairs, or equivalent industry experience). Author profiles are available at /team and on individual author pages.
Corrections and updates
If we publish an error, we correct it promptly and note the change with an updated
dateModified timestamp. To report a factual error, contact our editorial desk
via /us/contact with the article URL and
supporting source.
AI-assisted production
We use AI tools to assist research, drafting, and data enrichment. All published content is reviewed and edited by qualified staff before publication. Entity profiles (drugs, companies, trials) combine public regulatory data with editorial enrichment; see /about/data-sources for attribution.